News

Euclid Vision Announces Acquisition of Visionary Optics

Euclid Vision Corp., a global leader in advanced orthokeratology and proactive myopia management initiatives, is pleased to announce its acquisition of Visionary Optics, a specialty scleral contact lens design and distribution pioneer. The acquisition signifies Euclid’s recognition of the value of joining forces with Visionary Optics, the only company in the US that concentrates almost exclusively on scleral contact lenses. The union of these two companies increases each establishment’s ability to provide comprehensive specialty contact lens care to more patients globally.

“We are excited about joining forces with Visionary Optics. This union opens exciting opportunities for cross-company collaboration and innovation,” said Joseph Boorady, Euclid President and CEO. “Visionary Optics, with its best-in-class scleral lens innovations and world class customer service, is a great match for the Euclid portfolio. Having market leading technologies in two of the fastest growing specialty contact lens markets — Ortho-K and scleral lenses — positions us to better serve our customers and their patients.”

Euclid and Visionary Optics share many of the same cultural values, such as a dedication to professional education, strong partnerships with eye care professionals, and market savvy product innovation. Each company will retain their unique individual brand, while being perfectly positioned to reap the benefits of shared future endeavors.

“This is an incredible opportunity for Visionary Optics to work with a partner who can help take our business and technology to the next level, while also maintaining the key foundational aspects of what has fueled our success including our customer-driven corporate culture and high-tech research orientation,” said Donald Sanders, MD, PhD Visionary Optics President and CEO.

Euclid and Visionary Optics understand that clinicians partner with companies that not only offer unparalleled lens design and the highest-level of advanced manufacturing, but those that also provide exceptional customer service. “Expert customer service is critical to the success of the clinicians who work with us, and we pride ourselves on the level of expertise for which our customer service team is known,” said Dr. Sanders. “As we unite with Euclid, preserving these team values are integral to maintaining our role as a leader in scleral lens design and distribution. Thus, our customers can count on the same great service they are used to with Visionary Optics.”

Recent News

06/02/2026

TearSolutions Receives FDA Orphan Drug and Fast Track Designations for Lacripep® in Neurotrophic Keratitis and Initiates Phase 2 Clinical Trial with First Patients Dosed

TearSolutions, Inc. (“TearSolutions”), a clinical-stage biotechnology company developing novel ophthalmic therapeutics, today announced receiving Food and Drug Administration (FDA) Orphan Drug (ODD) and Fast Track Designations for Lacripep in Neurotrophic Keratitis (NK) and initiating a Phase 2 clinical trial with first patients dosed. The FDA’s ODD provides incentives, including tax credits for clinical testing and

06/02/2026

Contraline Announces $92.5 Million Series B Financing to Advance NES/T Male Contraceptive into Late-Stage Development

Contraline, Inc., a clinical-stage biopharmaceutical company developing novel male contraceptives, today announced the closing of a $92.5 million Series B financing co-led by BVF Partners L.P. and RA Capital Management, with participation from GV (Google Ventures), Lumira Ventures, Invus, and other new and existing investors. In conjunction with the closing of the Series B financing,

06/02/2026

GEN Names BioHealth Capital Region a Top 3 U.S. Biopharma Cluster for Fourth Year in a Row

The BioHealth Capital Region, spanning Maryland, Virginia, and Washington, D.C., has once again been named one of the nation’s Top 3 biopharma clusters by Genetic Engineering & Biotechnology News (GEN), marking the region’s fourth consecutive year in the Top 3. GEN’s 2026 “Top 10 U.S. Biopharma Clusters” ranking was authored by Alex Philippidis, Senior Business